Comgest Global Investors S.A.S. Sells 13,291 Shares of Medtronic PLC $MDT

Comgest Global Investors S.A.S. lowered its position in Medtronic PLC (NYSE:MDT) by 36.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 23,384 shares of the medical technology company’s stock after selling 13,291 shares during the quarter. Comgest Global Investors S.A.S.’s holdings in Medtronic were worth $2,227,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Corundum Trust Company INC bought a new stake in Medtronic in the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. purchased a new stake in shares of Medtronic during the third quarter worth about $29,000. Delos Wealth Advisors LLC bought a new stake in shares of Medtronic in the 2nd quarter worth approximately $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic in the third quarter valued at $33,000. Finally, Tripletail Wealth Management LLC purchased a new position in shares of Medtronic during the third quarter valued at about $34,000. Institutional investors own 82.06% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat on revenue and EPS; management reaffirmed FY26 guidance (EPS range ~5.62–5.66) while highlighting strength in Cardiovascular (cardiac ablation) and Diabetes — the core growth drivers behind the move higher. Medtronic beats quarterly profit estimates
• Positive Sentiment: Commercial/technology catalysts: Medtronic completed first U.S. Hugo robotic surgical cases — a notable commercialization milestone — and received FDA clearance for Infuse bone graft in TLIF procedures, supporting medium‑term growth and product-led upside. Medtronic completes first U.S. cases with Hugo
• Neutral Sentiment: Management: Q3 call and transcripts provide detail on segment performance and investments; while results were solid, commentary showed investment spending and FX dynamics that will influence margin trajectory. Q3 earnings call transcript
• Neutral Sentiment: Product pipeline activity continues: MiniMed Flex submitted to FDA (diabetes separation plan continues) — a longer‑term structural positive but not an immediate earnings lever. MiniMed Flex submission
• Negative Sentiment: Margin and cost headwinds: company noted margin pressure from tariffs and higher costs — profit fell despite higher revenue, which tempers the upside from the top‑line beat. Profit Falls Despite Higher Revenue
• Negative Sentiment: Analyst reactions mixed and some price targets trimmed: several shops cut forecasts or nudged targets lower (JPMorgan, Baird, Leerink adjustments), reflecting more cautious medium‑term margin assumptions even as some firms reaffirm buys. JPMorgan price target lowered
• Negative Sentiment: Legal/competitive overhangs and mixed commentary: some market pieces flag litigation and competitive/legal noise (Masimo-related themes) that could add near‑term volatility to the investment case. Is Mixed Q3 Results, Robotics Win and Legal Hit Altering The Investment Case

Medtronic Stock Performance

Shares of Medtronic stock opened at $98.51 on Thursday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The firm’s 50-day moving average is $99.14 and its 200 day moving average is $96.59. The stock has a market cap of $126.29 billion, a price-to-earnings ratio of 27.44, a PEG ratio of 2.54 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MDT shares. Sanford C. Bernstein raised their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. CICC Research began coverage on Medtronic in a report on Friday, January 30th. They issued an “outperform” rating for the company. Daiwa Securities Group raised their price objective on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Finally, Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $111.05.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).